Cytek Biosciences (CTKB) Stock Analysis & Winston Score

Cytek Biosciences makes specialized scientific instruments used in biology and medical research. Its main product is a type of machine called a flow cytometer, which scientists use to analyze cells in detail — helpful for studying diseases like cancer and developing new drugs. The company sells primarily to research universities, hospitals, pharmaceutical companies, and biotech labs around the world. Cytek earns money by selling its instruments upfront and then generating recurring revenue from reagents (the chemical supplies needed to run tests) and service contracts. The company operates globally, with customers across North America, Europe, and Asia, and had roughly $160 million in annual revenue in recent fiscal periods. Its competitive edge comes from its "full-spectrum" technology, which captures more biological data per test than older systems — making it harder for customers to switch once they've built workflows around it. The key risk is that research funding, especially from government sources like the NIH, can be cut, which would reduce demand for new instruments.